Scorpius Holdings Announces Contract with Premier Clinical-Stage Biotech Company; Opens Door to Future GMP Manufacturing Opportunities
30 Setembro 2024 - 9:00AM
Scorpius Holdings, Inc. (NYSE American:
SCPX) (“Scorpius” or “the Company”), an integrated
contract development and manufacturing organization ("CDMO"), today
announced it has signed a contract to provide bioanalytical
services for a publicly traded clinical-stage immuno-oncology
company.
This collaboration opens the door for further
opportunities, as Scorpius expects to expand its services to
include additional analytical work and future GMP manufacturing
upon completion of this initial phase. This contract underscores
Scorpius’ expertise in delivering critical bioanalytical and
process development services, further establishing its role as a
trusted partner in the biologics manufacturing space.
Jeff Wolf, CEO of Scorpius, commented, "This
important contract is a clear validation of Scorpius’ comprehensive
capabilities which include advanced bioanalytical services. Our
state-of-the-art bioanalytical and process development facilities
enable us to offer an integrated solution that meets the diverse
needs of biologics manufacturers. We are excited by the potential
to develop this partnership further and to offer ongoing
bioanalytical support and future GMP manufacturing services to help
advance this client’s clinical programs.”
Scorpius Holdings, Inc.
Scorpius Holdings, Inc. is an integrated
contract development and manufacturing organization (CDMO) focused
on rapidly advancing biologic and cell therapy programs to the
clinic and beyond. Scorpius offers a broad array of analytical
testing, process development, and manufacturing services to
pharmaceutical and biotech companies at its state-of-the-art
facilities in San Antonio, TX. With an experienced team and new,
purpose-built U.S. facilities, Scorpius is dedicated to transparent
collaboration and flexible, high-quality biologics
biomanufacturing. For more information, please visit
www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. In some cases, forward-looking statements can be
identified by terminology such as "may," "should," "potential,"
"continue," "expects," "anticipates," "intends," "plans,"
"believes," "estimates," and similar expressions, and include
statements such as Scorpius expanding its services to include
additional analytical work and future GMP manufacturing upon
completion of the initial phase of the contract;. and the potential
to develop the partnership further and to offer ongoing
bioanalytical support and future GMP manufacturing services to help
advance this client’s clinical programs contributing its
proprietary scientific expertise and resources to accelerate
innovations aimed at Important factors that could cause actual
results to differ materially from current expectations include,
among others, the ability of the Company to derive the anticipated
benefits from the partnership including expanding the services to
be provided the Company’s ability to expand its large molecule
biomanufacturing CDMO services, attract new customers, profit from
its pipeline and continue to grow revenue; the ability to capture a
meaningful market share; the ability to generate meaningful cash
flow and become cash flow positive; the Company’s financing needs,
its cash balance being sufficient to sustain operations and its
ability to raise capital when needed, the Company’s ability to
leverage fixed costs and achieve long-term profitability; the
Company’s ability to obtain regulatory approvals or to comply with
ongoing regulatory requirements, regulatory limitations relating to
the Company’s ability to successfully promote its services and
compete as a pure-play CDMO, and other factors described in the
Company’s annual report on Form 10-K for the year ended December
31, 2023, subsequent quarterly reports on Form 10-Qs and any other
filings the Company makes with the SEC. The information in this
presentation is provided only as of the date presented, and the
Company undertakes no obligation to update any forward-looking
statements contained in this presentation on account of new
information, future events, or otherwise, except as required by
law.
Media and Investor Relations
ContactDavid Waldman+1 919 289
4017ir@scorpiusbiologics.com
Scorpius (AMEX:SCPX)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Scorpius (AMEX:SCPX)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024